375815-87-5

Basic information

• Product Name: Varenicline tartrate
• Synonyms: VARENICLINE TARTRATE;Varenicline tartrate for research;7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine (2R,3R)-2,3- dihydroxybutanedioate;Champix;CP 526555-18;6,10-Methano-6H-pyrazino(2,3-H)(3)benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1);Unii-82269asb48;,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-
• CAS NO: 375815-87-5
• Molecular Formula: C₄H₆O₆*C₁₃H₁₃N₃
• Molecular Weight: 361.34926
• EINECS: 200-659-6
• Product Categories: Heterocyclic Compounds;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;APIs;Pfizer compounds;Chantix, Champix;Inhibitors
• Mol File: 375815-87-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 206-208°C
• Boiling Point: 400.6 °C at 760 mmHg
• Flash Point: 196.1 °C
• Appearance: white to beige/
• Vapor Pressure: 1.25E-06mmHg at 25°C
• Storage Temp.: Desiccate at RT
• Solubility: DMSO: >5mg/mL
• CAS DataBase Reference: Varenicline tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: Varenicline tartrate(375815-87-5)
• EPA Substance Registry System: Varenicline tartrate(375815-87-5)

Safety Data

• Hazard Codes: Xn,N,T,F
• Statements: 22-50-39/23/24/25-23/24/25-11
• Safety Statements: 22-57-45-36/37-16-7
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 375815-87-5(Hazardous Substances Data)

Usage

Chemical Properties

Tan Solid

Uses

Different sources of media describe the Uses of 375815-87-5 differently. You can refer to the following data:
1. Nicotinic a4? acetylcholine receptor partial agonist. Aid in smoking cessation.
2. Nicotinic α4β2 acetylcholine receptor partial agonist. Aid in smoking cessation.
3. Varenicline tartrate is a prescription medication used to treat smoking addiction. Varenicline is a nicotinic receptor partial agonist. In this respect, it is similar to cytisine and different from the nicotinic antagonist, bupropion, and nicotine replacement ther

Definition

ChEBI: A tartrate salt obtained by reaction of varenicline with one equivalent of (R,R)-tartaric acid. A partial agonist for nicotinic cholinergic receptors, it is used as an aid to giving up smoking.

Biological Activity

Orally active, subtype-selective partial agonist at α 4 β 2 nicotinic receptors (K i values are 0.06, 240, 322 and 3540 nM for α 4 β 2, α 3 β 4, α 7, α 1 β γ δ receptors respectively). Reduces nicotine-evoked dopamine release in vitro and decreases nicotine self-administration in vivo .

Biochem/physiol Actions

Varenicline tartrate is a partial α4β2 nicotinic receptor agonist and α7 full agonist. Varenicline competitively binds to α4β2 receptors and partially stimulates without creating a full nicotine effect, while simultaneoudly blocking the ability of nicotine to bind to the receptors. Varenicline thus blocks the ability of nicotine to activate α4β2 receptors and stimulate the central nervous mesolimbic dopamine system, believed to be the neuronal mechanism underlying reinforcement and reward experienced upon smoking.

InChI:InChI=1/C13H13N3.C4H6O6/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1;5-1(3(7)8)2(6)4(9)10/h1-2,4-5,8-9,14H,3,6-7H2;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.0/s1

Upstream product

• 230615-70-0 1-(9,10-dihydro-6H-6,10-methanoazepino[4,5-g]quinoxaline-8(7H)-yl)-2,2,2,-trifluoroethanone 
• 230615-69-7 1-(7,8-diamino-4,5-dihydro-1H-1,5-methanobenzo[d]azepin-3(2H)-yl)-2,2,2-trifluoroethanone 
• 87-69-4 L-Tartaric acid 
• 249296-44-4 varenicline 

Relevant articles and documents

CRYSTALLINE FORMS OF NOVEL VARENICLINE SALTS, PREPARATION METHODS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF

The present invention refers to crystalline form of 7, 8, 9, 10 - tetrahydro - 6, 10 - methano - 6H - [3] [2, 3 a-h] pyrazole roh it cuts the person number pin new salt, and manufacturing method of including pharmaceutical compositions are disclosed. (by machine translation)

HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY

Provided herein is an impurity of varenicline, 6-methyl-5,8,14-triazatetracyclo[l 0.3.1.02'n,04'9]hexadeca-2(l l),3,5,7,9-pentaene (methylvarenicline) impurity, and a process for the preparation and isolation thereof. Provided further herein is a highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity, a process for the preparation thereof, and pharmaceutical compositions comprising highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity.

PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

Provided herein is an improved, convenient, commercially viable and environmentally friendly process for the preparation of varenicline or a pharmaceutically acceptable salt thereof comprising reacting l-(4,5-diamino-10-aza-tricyclo[6.3.1.02 7]dodeca-2(7),3,5-trien- 10-yl)-2,2,2-trifluoro-ethanone with chloroacetaldehyde in the pressence of an oxygen source. Provided further herein is an improved and industrially advantageous process for the preparation of l-(4,5-diamino-10-aza-tricyclo[6.3.1.02 7]dodeca-2(7),3,5-trien-10-yl)-2,2,2- trifluoro-ethanone.